Indivior Strengthens Board with New Appointment

The latest update is out from Indivior ( (GB:INDV) ).

Indivior PLC has appointed Daniel A. Ninivaggi as an Independent Non-Executive Director to its Board, effective January 31, 2025. Ninivaggi brings extensive public company experience and expertise in operations, capital allocation, and legal and finance, which is expected to enhance Indivior’s mission to transform the lives of patients struggling with opioid use disorder. This strategic leadership change is anticipated to strengthen Indivior’s position as a global leader in OUD treatments, benefiting stakeholders and supporting the company’s continued growth.

More about Indivior

Indivior is a global pharmaceutical company focused on developing medicines for substance use disorders (SUD), with a vision to provide evidence-based treatment for chronic conditions and co-occurring disorders of SUD worldwide. Headquartered in Richmond, VA, Indivior has a strong portfolio of opioid use disorder (OUD) treatments and a pipeline of product candidates to expand its reach, with its products available in over 30 countries.

YTD Price Performance: -6.49%

Average Trading Volume: 278,042

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £1.19B

See more data about INDV stock on TipRanks’ Stock Analysis page.